Why Seizure Medications Treat Nerve Pain

Sciatica is one of the most common and most disabling forms of nerve pain I treat in clinical practice. The radiating pain, numbness, and weakness that travel from the lower back into the leg reflect compression or irritation of a spinal nerve root — a problem that is structural at its origin but neurological in its expression. Understanding that distinction matters when it comes to selecting treatment, because the medications that work best for nerve pain are not the ones most patients expect. Among the most effective and most misunderstood are the medications originally developed for epilepsy — gabapentin and pregabalin chief among them.

THE BASICS

Why Seizure Medications Treat Nerve Pain

Gabapentin and pregabalin belong to a class of medications that work by binding to the α2δ-1 subunit of voltage-gated calcium channels on nerve cell membranes. By reducing calcium influx into the neuron, they decrease the release of excitatory neurotransmitters — particularly glutamate — that are responsible for amplifying and transmitting pain signals. The result is a quieting of abnormal nerve firing, which is precisely the mechanism driving neuropathic pain. The nerve is not simply transmitting a pain signal from a damaged structure — it has become dysregulated, firing in patterns that no longer accurately represent what is happening in the tissue. Gabapentinoids address that dysregulation directly, which is why they work for nerve pain in a way that anti-inflammatory medications and opioids often do not.

In the context of sciatica and lumbosacral radiculopathy, where nerve root compression produces inflammation and altered nerve conduction, these medications can provide meaningful relief that allows patients to participate in physical therapy, restore function, and avoid or delay more invasive interventions. Their use in neuropathic pain is well-established and supported by a substantial clinical evidence base, even though their origin as antiepileptic agents sometimes creates confusion for patients encountering them for the first time.

CLINICAL EVIDENCE

What Does the Research Show?

The evidence for gabapentin in neuropathic pain is among the most robust in this category of medication. A systematic review of randomized controlled trials involving more than 5,900 participants demonstrated that gabapentin at doses ranging from 1,200 to 3,600 milligrams daily achieves at least 50 percent reduction in pain intensity in a clinically meaningful proportion of patients. In postherpetic neuralgia — one of the most well-studied neuropathic pain conditions — 32 percent of patients on gabapentin achieved substantial pain relief compared to 17 percent on placebo, with an additional 46 percent experiencing moderate benefit. Similar efficacy data exist for painful diabetic neuropathy, chemotherapy-induced peripheral neuropathy, and radiculopathy. Pregabalin carries a comparable mechanism and evidence profile with more predictable pharmacokinetics, which can make titration more straightforward in some patients. Neither medication is universally effective — neuropathic pain is heterogeneous and individual response varies — but the proportion of patients who benefit meaningfully is large enough that these agents deserve serious consideration in any comprehensive nerve pain management plan.

PATIENT SELECTION

When These Medications Are and Are Not the Right Choice

Gabapentinoids are most appropriate for patients with confirmed neuropathic pain — pain that is burning, electric, shooting, or associated with hypersensitivity, allodynia, or dermatomal numbness and weakness — rather than purely mechanical or inflammatory pain. In my practice they are one component of a multimodal treatment strategy, not a standalone solution. Physical therapy addressing the underlying mechanical contributors to nerve compression, activity modification, and interventional procedures when indicated remain essential elements of care. Gabapentin or pregabalin can create the neurological window that allows those other treatments to work — reducing the pain burden enough that rehabilitation becomes possible and function begins to return.

The most common side effects are dizziness, sedation, and peripheral edema, all of which are dose-dependent and generally manageable with careful titration. More significant concerns include cognitive effects in older adults, mood disturbances, and the potential for dependence with long-term use — considerations that require individualized risk-benefit assessment and regular monitoring. These are not medications to prescribe reflexively or to continue indefinitely without reassessment. They are tools with a specific indication, a defined evidence base, and a role that is most valuable when their use is deliberate and time-limited where possible.

Other pharmacological options for neuropathic pain include tricyclic antidepressants such as amitriptyline and SNRIs such as duloxetine, both of which carry strong evidence particularly for diabetic neuropathy and can be preferable in patients where sedation or other gabapentinoid side effects are prohibitive. Topical agents including lidocaine and capsaicin preparations offer localized benefit with minimal systemic exposure. When pharmacological management is insufficient, interventional options including epidural steroid injections, selective nerve root blocks, and in refractory cases spinal cord stimulation, provide escalating levels of targeted treatment.

FOR REFERRING CLINICIANS

Patients with sciatica and lumbosacral radiculopathy frequently present having already tried gabapentin or pregabalin with incomplete response — either because the dose was subtherapeutic, the diagnosis driving the nerve pain was not precisely identified, or the medication was used in isolation without addressing the structural pain generator. I offer comprehensive electrodiagnostic evaluation including EMG and nerve conduction studies to characterize the radiculopathy, targeted interventional procedures including transforaminal epidural injections and selective nerve root blocks to address the structural component, and individualized pharmacological optimization as part of a coordinated management plan. I welcome direct physician-to-physician consultation.

PERSPECTIVE

A Note on Treating the Nerve, Not Just the Pain

One of the most important conceptual shifts in pain medicine over the past two decades has been the recognition that neuropathic pain is not simply pain that happens to involve a nerve — it is a distinct physiological state in which the nervous system itself has become the problem. The compressed disc or narrowed foramen may be the inciting event, but the ongoing pain is maintained by neurological mechanisms that require neurologically targeted treatment. Gabapentinoids address those mechanisms directly, and when used appropriately — at therapeutic doses, in the right diagnostic context, as part of a comprehensive plan — they can meaningfully change the trajectory of a patient's recovery. What I try to avoid is the pattern I see too often in practice: a patient on a low, ineffective dose of gabapentin for years, with no interventional evaluation, no structured rehabilitation, and no reassessment of whether the medication is still serving a purpose. Nerve pain deserves better than that, and so do the patients who live with it.

DISCLOSURE & REFERENCES

This article is for educational purposes and reflects clinical experience and interpretation of published literature. It is not a substitute for individualized medical evaluation. Key references: Wiffen PJ et al. 2017 (gabapentin for chronic neuropathic pain, Cochrane Review); Moore RA et al. 2014 (pregabalin for neuropathic pain, Cochrane Review); Finnerup NB et al. 2015 (pharmacotherapy for neuropathic pain, Lancet Neurol); Attal N et al. 2010 (EFNS guidelines on neuropathic pain pharmacotherapy); Baron R et al. 2010 (neuropathic pain mechanisms, Nat Rev Neurosci).

ABOUT THE AUTHOR

Dr. Mahajer is a double board-certified physiatrist and sports medicine physician, fellowship-trained in Interventional Spine & Sports Medicine at the Icahn School of Medicine at Mount Sinai. He is an Assistant Professor of Neuroscience at FIU Herbert Wertheim College of Medicine. He is the Immediate Past President of the American Osteopathic College of Physical Medicine and Rehabilitation (AOCPMR), holds medical licenses in Florida, New York, and California, and has been recognized as a Top Physiatrist and Top Doctor in both Florida and New York.